HC Wainwright Forecasts Kairos Pharma FY2026 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Kairos Pharma in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.38) per share for the year. HC Wainwright also issued estimates for Kairos Pharma’s FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.73) EPS.

Kairos Pharma Stock Performance

Shares of NYSEAMERICAN:KAPA traded down $0.03 on Tuesday, reaching $0.59. The company’s stock had a trading volume of 14,089 shares, compared to its average volume of 503,030. The company has a 50-day simple moving average of $0.61 and a 200 day simple moving average of $0.82. Kairos Pharma has a 52-week low of $0.40 and a 52-week high of $2.11. The company has a market cap of $12.67 million, a P/E ratio of -1.97 and a beta of 1.97.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.07) earnings per share for the quarter.

Institutional Investors Weigh In On Kairos Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in shares of Kairos Pharma in the 2nd quarter worth approximately $44,000. Two Sigma Investments LP bought a new position in Kairos Pharma during the third quarter valued at $54,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Kairos Pharma in the third quarter valued at $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.